Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2286672 | 0.81 | MAPT (0.40) | MAPTCACNA1BAPBA1CYP3A4TSHR | |
| SCHEMBL2516533 | 0.81 | MAPT (0.40) | MAPTCACNA1BAPBA1CYP3A4TSHR | |
| SCHEMBL5341469 | 0.81 | MAPT (0.40) | MAPTCACNA1BAPBA1CYP3A4TSHR | |
| SCHEMBL3637092 | 0.79 | MAPT (0.39) | MAPTCACNA1BAPBA1CYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL6573325 | 0.79 | MAPT (0.39) | MAPTCACNA1BAPBA1CYP3A4TSHR | |
| SCHEMBL8824184 | 0.79 | TSHR (0.43) | MAPTCACNA1BAPBA1CYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL2302945 | 0.79 | MAPT (0.39) | MAPTCACNA1BAPBA1CYP3A4TSHR | |
| SCHEMBL3634048 | 0.79 | MAPT (0.39) | MAPTCACNA1BAPBA1CYP3A4TSHR | |
| SCHEMBL2355766 | 0.79 | PTGS1 (0.43) | MAPTCACNA1BAPBA1CYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL2302935 | 0.79 | MAPT (0.39) | MAPTCACNA1BAPBA1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968620-B1 | Compositions comprising powdered garlic (Allium sativum linn.) and a concentrate of organic selenium compounds for nutritional supplementation | MAJEED MUHAMMED (US) | 2012-04-18 | — | — | EP | claimed |
| US-20060240126-A1 | COMPOSITIONS CONTAINING ALLIUM SATIVUM LINN. (GARLIC) NATURALLY ENRICHED WITH ORGANIC SELENIUM COMPOUNDS FOR NUTRITIONAL SUPPLEMENTATION | SAMI LABS LIMITED | 2006-10-26 | — | — | US | claimed |
| WO-2005023274-A1 | TREATMENT AND PREVENTION OF INFLAMMATORY DISEASE AND MITOCHONDRIAL DYSFUNCTION WITH HIGH DOSE SELENIUM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2005-03-17 | — | — | WO | claimed |
| US-20240115666-A1 | COMPOSITIONS AND METHODS FOR REDUCING GAMMA-GLUTAMYLTRANSFERASE LEVELS | LILE METHOD RESEARCH, LLC (US) | 2024-04-11 | — | — | US | disclosed |
| US-20240108695-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND/OR TREATING TUBERCULOSIS AND MRSA | LILE METHOD RESEARCH, LLC (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240108682-A1 | COMPOSITIONS AND METHODS FOR INCREASING GLUTATHIONE LEVELS | LILE METHOD RESEARCH, LLC (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240108696-A1 | COMPOSITIONS AND METHODS FOR IMPROVING VACCINE THERAPY | LILE METHOD RESEARCH, LLC (US) | 2024-04-04 | — | — | US | disclosed |
| WO-2024064264-A2 | COMPOSITIONS AND METHODS FOR INCREASING GLUTATHIONE LEVELS | LILE METHOD RESEARCH, LLC (US) | 2024-03-28 | — | — | WO | disclosed |
| EP-1968620-B1 | Compositions comprising powdered garlic (Allium sativum linn.) and a concentrate of organic selenium compounds for nutritional supplementation | MAJEED MUHAMMED (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20070026090-A1 | Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-02-01 | — | — | US | disclosed |
| US-20060240126-A1 | COMPOSITIONS CONTAINING ALLIUM SATIVUM LINN. (GARLIC) NATURALLY ENRICHED WITH ORGANIC SELENIUM COMPOUNDS FOR NUTRITIONAL SUPPLEMENTATION | SAMI LABS LIMITED | 2006-10-26 | — | — | US | disclosed |
| WO-2005023274-A1 | TREATMENT AND PREVENTION OF INFLAMMATORY DISEASE AND MITOCHONDRIAL DYSFUNCTION WITH HIGH DOSE SELENIUM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108695-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND/OR TREATING TUBERCULOSIS AND MRSA | GGT1, GPX1, GCLC | MAPT 410/4885CACNA1B 4482/4885APBA1 2695/4885 |
| US-20240115666-A1 | COMPOSITIONS AND METHODS FOR REDUCING GAMMA-GLUTAMYLTRANSFERASE LEVELS | GGT1, GGCT, TGM2 | MAPT 477/4885CACNA1B 4695/4885APBA1 2653/4885 |
| US-20240108682-A1 | COMPOSITIONS AND METHODS FOR INCREASING GLUTATHIONE LEVELS | GGT1, GPX1, GSS | MAPT 555/4885CACNA1B 4633/4885APBA1 2851/4885 |
| US-20240108696-A1 | COMPOSITIONS AND METHODS FOR IMPROVING VACCINE THERAPY | GGT1, GPX1, TGM2 | MAPT 347/4885CACNA1B 4456/4885APBA1 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.